• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novartis launches MS study using data collected from smartphones

August 22, 2017 By Sarah Faulkner

NovartisNovartis (NYSE:NVS) said today that it is launching a research study to better understand the daily challenges facing people with multiple sclerosis. The study is designed to collect data from physical tasks and symptoms using participants’ smartphones.

The company said it hopes to find new potential ways to measure treatment effectiveness.

The elevateMS study, developed with Sage Bionetworks, uses a mobile app built on the Apple ResearchKit platform. The app was designed with input from patients, who provided feedback on the app’s user interface and helped determine what the study should measure, according to Novartis.

The app records participant responses to questionnaires and monitors movement data and task performance. Study participants will be able to track their data over time, the company said.

“As physicians, we always want to know how our patients with MS are doing on the treatments we prescribe,” Dr. Stanley Cohan, medical director of the Providence Multiple Sclerosis Center, said in prepared remarks. “With the elevateMS app, study participants can frequently document their symptoms in a personal health story. In turn, this data may provide researchers with new ways to look at disease progression and treatment effectiveness.”

Cohan is a scientific advisor to the elevateMS study.

Novartis has three medications that are approved to treat MS, as well as investigational therapies at various stages of development.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Clinical Trials, Featured, Neurological, Pharmaceuticals, Technology, Wall Street Beat Tagged With: Novartis

IN CASE YOU MISSED IT

  • Rapid Dose closes first tranche of $5M financing
  • Senseonics stock is up as it sticks by revenue guidance
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS